References
- Mead GM, Sydes MR, Walewski J, . An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002;13:1264–1274.
- Corazzelli G, Frigeri F, Russo F, . RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and “unclassifiable” highly aggressive B-cell lymphoma. Br J Haematol 2012;156:234–244.
- Romaguera JE, Fayad L, Rodriguez MA, . High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013–7023.
- Kelly JL, Toothaker SR, Ciminello L, . Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma 2009;9:307–310.
- Kasamon YL, Brodsky RA, Borowitz MJ, . Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia. Leuk Lymphoma 2013;54:483–490.
- Wilson WH, Grossbard ML, Pittaluga S, . Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 2002;99: 2685–2693.
- Dunleavy K, Pittaluga S, Wayne A, . MYC+ aggressive B-cell lymphomas: novel therapy of untreated Burkitt lymphoma (BL) and MYC+ diffuse large B-cell lymphoma (DLBCL) with DA-EPOCH-R. Ann Oncol 2011;22(Suppl. 4): Abstract 071.
- Schmitz R, Young RM, Ceribelli M, . Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012490:116–120.
- Sander S, Calado DP, Srinivasan L, . Synergy between PI3K Signaling and MYC in Burkitt lymphomagenesis. Cancer Cell 2012;22:167–179.
- Spender LC, Inman GJ. Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics. Mol Cancer Res 2012;10:347–359.